DIAZEPAM (diazepam) by Medica Corp is clinical pharmacology in animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Approved for epilepsy, alcohol withdrawal syndrome, seizures. First approved in 1990.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
Diazepam is a benzodiazepine administered via intramuscular injection for acute management of epilepsy, seizures, and alcohol withdrawal syndrome. It acts on the limbic system, thalamus, and hypothalamus to produce calming effects without extrapyramidal side effects. The drug achieves rapid CNS penetration with a Tmax of approximately 1.5 hours and has a long-acting metabolite (desmethyldiazepam) with a Tmax of ~61 hours.
Product approaching loss of exclusivity with legacy-stage commercial expectations; smaller team focus on defending market share against newer anticonvulsants.
CLINICAL PHARMACOLOGY In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side…
Benzodiazepine
Worked on DIAZEPAM at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With Epilepsy
Treatment Of Alcohol Withdrawal Syndrome: Dexmedetomidine Vs Diazepam In A Hospital O'horán
Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With Epilepsy
A Study of Diazepam After Intranasal and Intravenous Administration to Healthy Volunteers
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on diazepam offers limited career trajectory as the product approaches loss of exclusivity with minimal innovation pipeline and no active clinical expansion. Positions are primarily in defensive commercial and market access roles focused on generic competition management and specialty channel penetration rather than growth initiatives.